Cross-reactivity of SARS-CoV-2 with HIV chemiluminescent assay leading to false-positive results

HIV may be considered as a differential diagnosis for patients who present with prolonged fever and respiratory symptoms. During the COVID-19 pandemic, several patients from our institution have had a simultaneous screening test for serum HIV antigen/antibodies as well as a nasopharyngeal swab for SARS-CoV-2 real-time reverse transcription PCR (rRT-PCR) on presentation to the hospital. While the molecular results often have a delayed turnaround time in light of increased testing volume, HIV screen performed as a chemiluminescent immunoassay on our Abbott Architect platform (Abbott Laboratories, Abbott Park, Illinois, USA) has a testing time of only 30 min. Herein, we retrospectively reviewed and identified two positive COVID-19 cases on rRT-PCR who concurrently tested reactive for HIV on the Architect, with further confounding results.

Both patients were admitted and tested in the same month. Our first patient was a man in his early 20s who had no significant medical history, presenting with a persistent fever for 2 days, dry cough and pharyngitis. He was not on any long-term medications. His initial laboratory investigations revealed white blood cells of 5.85x10^9/litre (3.84–10.01), haemoglobin 144 g/L (131–166), haematocrit 43.7% (40.3–50.3), platelets 233x10^9/L (131–145), potassium 3.9 mmol/L (3.5–5.0). His first nasopharyngeal swab similarly tested positive for SARS-CoV-2 and a concurrent HIV test on the Abbott Architect platform was reactive at 1.11xCO. Neither of the patients reported previous blood transfusions, intravenous drug use or drug therapies, which may interact with testing.

These two patients’ serum samples were repeated on a different Abbott Architect platform in a separate institution, which continued to show reactivity on the HIV chemiluminescent immunoassay. Their sera were then followed up by testing on a fourth generation, VIDAS HIV duo assay (BioMérieux, Durham, North Carolina, USA), an enzyme-linked fluororescent assay, which combines the detection of anti-HIV-1 (groups M and O) and anti-HIV-2 total immunoglobulins with HIV-1 p24 antigens. Both sera were negative for this duo assay. Confirmatory testing was then performed on the MP Biomedicals HIV immuno blot, which was negative in both sera.

This article underscores several important learning points. We have shown for the first time that there is cross-reactivity of SARS-CoV-2 antigen/antibodies with commercial chemiluminescent immunoassays leading to a false-positive result. Kliger and Levanon via sequence analysis had shown that HIV and SARS-CoV viral proteins shared sequence motifs that construct their active confirmation, which may explain a certain degree of homology in their proteins. The limitation of HIV chemiluminescent assays may be compromised if treatment is initiated without relative caution. While the institutional ethics review board approved our study (DSRB: 2020/00407), the institutional ethics review board approved the final submission. None declared.

REFERENCES